Mineralys Therapeutics said its Chief Executive Officer, Jon Congleton, sold 15,730 shares of the company's common stock on April 13, 2026, realizing proceeds of approximately $421,979. The block was transacted at weighted-average prices that ranged from $26.81 to $26.96 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Congleton adopted on December 30, 2025. After completing the sale, he continues to directly own 689,321 shares of Mineralys Therapeutics.
Since the time of the transaction the stock has risen to $30.42, representing a 125% gain over the trailing 12 months. According to InvestingPro analysis, Mineralys appears undervalued on a Fair Value basis, and three analysts have recently revised earnings estimates upward. InvestingPro also notes that its Pro Research Report provides additional research coverage for MLYS and more than 1,400 U.S. equities.
On the corporate front, Mineralys reported fourth-quarter 2025 results that included an earnings-per-share figure of -0.4, outperforming the consensus forecast of -0.94. The better-than-expected EPS reading arrives amid investor scrutiny over rising general and administrative expenses and the implications of recent trial outcomes.
Analyst reactions to the company’s progress have been mixed. BofA Securities raised its price target to $51.00 and kept a Buy rating, citing continued clinical development gains for lorundrostat in uncontrolled hypertension. Stifel reiterated a Buy rating with a $52.00 price objective, pointing to the company’s advances toward commercial readiness following the FDA’s acceptance of the New Drug Application. By contrast, Jefferies trimmed its price target to $30 from $42 and maintained a Hold rating, noting uncertainty about the strategic path for lorundrostat as the December PDUFA date approaches.
Separately, Mineralys appointed Jeffrey A. Munsie as Chief Legal Officer, adding legal experience from prior roles in the biopharmaceutical sector. The company described the hire as part of ongoing efforts to strengthen its corporate and regulatory capabilities while advancing its drug-development pipeline.
Context and takeaways
- Insider transaction - The CEO sale was executed under a pre-specified Rule 10b5-1 plan and leaves Congleton with a significant personal stake.
- Operational progress - Q4 2025 results topped expectations on an EPS basis despite investor concern around expense trends and trial results.
- Analyst divergence - Brokerages have issued both higher and lower price targets, reflecting differing views on clinical progress and commercial prospects for lorundrostat.
Additional information provided with company updates
These corporate moves - insider selling under a Rule 10b5-1 program, a stronger-than-forecast quarter, an incoming chief legal officer, and varied analyst reactions - form the current public view of Mineralys as it advances toward regulatory milestones and potential commercialization activities.